Erratum: A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer (Clinical Cancer Research (2021) 27 (2470-2480) DOI: 10.1158/1078-0432.CCR-20-4632)

Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-EnríquezSeunghee Kim-Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original version of this article (1), the name of the thirty-third author, F. Stephen Hodi, is incorrect. The name has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Original languageEnglish (US)
Pages (from-to)4940
Number of pages1
JournalClinical Cancer Research
Volume27
Issue number17
DOIs
StatePublished - Sep 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer (Clinical Cancer Research (2021) 27 (2470-2480) DOI: 10.1158/1078-0432.CCR-20-4632)'. Together they form a unique fingerprint.

Cite this